Retrospective review assesses biologic therapy impact on asthma control in obese and non-obese adults, indicating effective treatment in both groups.
Key Points
This study aims to evaluate the effectiveness of biologic therapy on asthma control in obese versus non-obese patients.
Retrospective review of 108 adult asthma patients on biologic therapy at Cook County Hospital from January 2021 to August 2024.
Patients categorized as non-obese (BMI <30) or obese (BMI ≥30) and their asthma control assessed post-treatment for ≥6 months.
Parameters measured include well-controlled rates, nighttime symptoms, exacerbations, activity limitations, and rescue medication needs.
In non-obese patients, well-controlled rates improved from 9% to 55% and from 9% to 62% in obese patients (p < 0.001 for both).
Nighttime symptoms decreased significantly from 64% to 11% in non-obese and from 59% to 20% in obese patients (both p < 0.001).
No significant differences in treatment responses observed across both groups for nighttime symptoms, activity limitations, exacerbation episodes, and rescue medication need.